<DOC>
	<DOCNO>NCT01576029</DOCNO>
	<brief_summary>Primary Objective : - To compare continuation treatment docetaxel versus switch cabazitaxel regard time PSA ( Prostatic Specific Antigen ) progression ( TTP-PSA ) , patient Castration-Resistant Prostate Cancer ( CRPC ) , four cycle docetaxel , minor PSA response ( define reduction 1 % 49 % ) increase 24 % PSA level . Secondary Objectives : - PSA response rate - Overall survival ( OS ) - Incidence Adverse Events</brief_summary>
	<brief_title>Continued Treatment With Docetaxel Versus Switch Cabazitaxel After Minor Prostate Specific Antigen Response Docetaxel Patients With Castration-Resistant Metastatic Prostate Cancer</brief_title>
	<detailed_description>Screening : 21days ( +7 day ) Treatment : PSA progression Post-treatment Follow-up : 2 year</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : Documentation histological prostate cancer ; Patients metastatic CRPC ( CastrationResistant Metastatic Prostate Cancer ) progress hormone deprivation , include withdrawal antiandrogenclass drug least 4 week , 6 week bicalutamide document PSA decrease 3 month therapy ; Documentation metastasis imaging ( computerized tomography [ CT ] , magnetic resonance image [ MRI ] bone scan ) , patient PSA &lt; 20 ng/mL time inclusion Provide minor PSA response ( characterize reduction 1 % 49 % ) increase 24 % PSA level , relation value measure start docetaxel therapy , measure least 7 day fourth cycle docetaxel ; Patient receive 4 cycle docetaxel dose 75 mg/m2 ; ECOG performance status 0 1 ; Marrow , liver renal function within acceptable value ; PSA ≥ 2 ng/mL ; Testosterone level ≤ 50 ng/dL ( patient prior history orchiectomy ) . Exclusion criterion : Prior use chemotherapy , except docetaxel four cycle ; Documented disease progression treatment docetaxel ( first 4 cycle ) ; Patients metastases result neurological damage ; Inability continue receive gonadotropinreleasing hormone agonists patient prior history orchiectomy ; Use recombinant methionyl human granulocytecolony stimulate factor nonglycosylated ( GCSF ) 24 hour precede baseline ; Any current neoplasia past 5 year , except basal cell skin carcinoma squamous skin cell carcinoma ; Known seropositivity HIV ( Human immunodeficiency Virus ) ; Concomitant diseases , significant neurological psychiatric disease ; uncontrolled hypercalcemia serious comorbidity ; Hypersensitivity allergy study treatment . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>